PRPH Yes, I listened to it and was pretty satisfied with all the answers. The federal funding for testing under HRSA hasn't yet been renewed and may not be, but even at that he made it sound like they're still doing quite well with just testing being done thru insurance reimbursements and cash pay. The next two quarters tend to be lower (both were losses last year) but analysts project a Q2 profit. Someone asked if analysts have been pretty accurate with their estimates, Karkus said he doesn't give guidance, but if anything analysts have tended to be a little on the low side.
If I recall, he also said the genomics biz is expected to be launched in retail in 2nd half of this year. So we should be able to see where that's going pretty soon, but Karkus was very optimistic. If I recall correctly, The Equivir product he thinks is a no-brainer.
It's possible Karkus is a little over-optimistic on getting into biotech. But as he said yesterday, he's the largest shareholder and most of his wealth is in the company, so he's certainly not going to continue investing in drugs or therapies that don't show promise. If the studies stop coming in good, then it ends. If the studies continue to come in nicely, then at each stage of further proof, he can possibly bring in a drug company partner at higher and higher amounts as studies move along. It sounded like a reasonable plan.
I see the company's ties to retail drug stores as a big plus for the genomics biz, and we should know pretty soon if that's going to amount to anything or not. If it works out, then that should be worth plenty on its own, so that's more what I'm looking at, plus Karkus is still very optimistic about their lab business. They are expanding the square footage of their lab.
News 
Market Data 
Discover 
